133 completed. 133 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 133 | Completed 133 |
| Phase 2 | 19 | Completed 19 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BHV-7000 Responsive Neurostimulation System (RNS) Study BHV-700 - Epilepsy, Seizures | Phase 1 | Completed | Yale University | 5 | 2025-10-07 | 2026-10-21 |
| Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2) - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 8 | 2025-09-29 | 2026-04-03 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 NPT 2042 - Photosensitive Epilepsy, Epilepsy | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 5 | 2024-08-21 | 2025-07-16 |
| A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults Phenytoin (Ascoli), Phenytoin (Vega Baja) - Healthy | Phase 1 | Completed | Pfizer | 35 | 2024-07-03 | 2024-10-08 |
| Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy Leucine-Enriched Essential Amino Acid powder - Refractory Epilepsy, Drug Resistant Epilepsy | Phase 1 | Completed | Elizabeth Anne Thiele | 4 | 2024-05-10 | 2026-05-22 |
| Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations Lepsiramp, 0.5 Mg/mL Oral Suspension, Fycompa, 0.5 Mg/mL Oral Suspension - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Aya Mohammed Abdel Magid Abdel Hamid | 26 | 2024-03-07 | 2025-08-20 |
| Bioequivalence Study of Perampanel Tablets 10 mg Perampanel 10 MG, Fycompa 10Mg Tablet - Epilepsy | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2023-11-22 | 2024-06-10 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| Bioequivalence Study of Perampanel Tablets 12 mg Perampanel 12 MG, Fycompa 12 mg film-coated tablets - Epilepsy | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2023-09-14 | 2024-06-12 |
| Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK AUT00201, Placebo - Myoclonus Epilepsies, Progressive | Phase 1 | Completed | Autifony Therapeutics Limited | 6 | 2023-05-12 | 2025-03-25 |
| Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects NPT 2042 (bumetanide analog) or Matching Placebo - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 50 | 2022-10-20 | 2023-04-04 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy Diazepam Nasal Spray [Valtoco] - Epilepsy | Phase 1 / Phase 2 | Completed | Neurelis, Inc. | 36 | 2021-11-08 | 2026-10-20 |
| Tricaprilin Infantile Spasms Pilot Study Tricaprilin - Infantile Spasm | Phase 1 | Completed | Cerecin | 8 | 2021-11-01 | 2024-09-19 |
| Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures Xcopri - Partial Epilepsy | Phase 1 | Completed | SK Life Science, Inc. | 26 | 2021-05-27 | 2026-03-31 |
| A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects brivaracetam - Healthy Participants | Phase 1 | Completed | UCB Biopharma SRL | 12 | 2021-05-19 | 2023-03-13 |
| A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy Alprazolam - Epilepsy | Phase 1 | Completed | UCB Biopharma SRL | 14 | 2021-04-28 | 2022-06-30 |
| Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants TAVT-18 (sirolimus) - Tuberous Sclerosis Complex, Epilepsy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 5 | 2020-09-08 | 2024-05-16 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate Carisbamate - Healthy Subjects | Phase 1 | Completed | SK Life Science, Inc. | 33 | 2020-08-27 | 2021-10-07 |
Showing 20 of 133. Sign in to see all of them.
Seizures (13) · Drug Resistant Epilepsy (8) · Epilepsies, Myoclonic (6) · Epilepsies, Partial (6) · Lennox Gastaut Syndrome (5) · Bipolar Disorder (3) · Central Nervous System Diseases (3) · Tuberous Sclerosis (3) · Alzheimer Disease (2) · Migraine Disorders (2) · Neurocysticercosis (2) · Neuroinflammatory Diseases (2) · Sturge-Weber Syndrome (2) · Taeniasis (2)
Brain Diseases (133) · Nervous System Diseases (133) · Central Nervous System Diseases (130) · Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (17) · Neurologic Manifestations (16) · Epileptic Syndromes (13) · Epilepsy, Generalized (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Neoplasms (7) · Mental Disorders (6) · Neurocutaneous Syndromes (5) · Neurodegenerative Diseases (5)
eslicarbazepine acetate (29) · Lamotrigine (10) · Levetiracetam (6) · Oxcarbazepine (6) · Cannabidiol (5) · Valproic Acid (5) · perampanel (5) · Phenytoin (4) · Topiramate (4) · brivaracetam (4) · Carbamazepine (3) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3) · ezogabine (3) · Diazepam (2) · Digoxin (2)
Bial - Portela C S.A. (30) · GlaxoSmithKline (13) · Children's Hospital Medical Center, Cincinnati (4) · SK Life Science, Inc. (4) · Supernus Pharmaceuticals, Inc. (4) · NeuroPro Therapeutics, Inc. (3) · UCB Pharma (3) · University of Minnesota (3) · Eisai Inc. (2) · Eli Lilly and Company (2) · Humanis Saglık Anonim Sirketi (2) · Johns Hopkins University (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Mayo Clinic (2) · National Institute of Mental Health (NIMH) (2)
United States (68) · Portugal (8) · United Kingdom (7) · Australia (4) · Belgium (4) · Germany (4) · China (3) · France (3) · South Korea (3) · Brazil (2) · Egypt (2) · India (2) · South Africa (2) · Bulgaria (1) · Canada (1)
Eric H Kossoff, MD (2) · Manuel Vaz da Silva, MD, PhD (2) · Manuel Vaz-da-Silva, MD, PhD (2) · Marc Kamin, MD (2) · Masahiro Fujita, M.D. (2) · Alana M Flexman, MD (1) · Angelina Kakooza-Mwesige, MMed (1) · Anli Liu, MD (1)
PMID 29063814, PMID 31048098, PMID 18778916, PMID 20887370, PMID 23798472, PMID 25377429, PMID 25912051, PMID 26030709, PMID 26710961, PMID 27012680, PMID 27350662, PMID 28500900, PMID 29749279, PMID 29933272, PMID 31624633, PMID 31672143, PMID 32190059, PMID 32395709, PMID 34119901, PMID 36859467, PMID 37770111, PMID 38932723, PMID 39331837, PMID 40650667, PMID 41249688, PMID 41780062, PMID 42647177
2018 (3), 2017 (1), F31NR010645 (1), R01NS065840 (1), R01NS074409 (1), R01NS094257 (1), U54NS078059 (1)